NovoCure (NASDAQ:NVCR – Get Free Report) had its price target reduced by equities research analysts at Wells Fargo & Company from $20.00 to $15.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 16.37% from the stock’s current price.
NVCR has been the subject of several other reports. Wedbush increased their target price on shares of NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. JPMorgan Chase & Co. assumed coverage on shares of NovoCure in a research report on Monday, July 13th. They set a “neutral” rating and a $17.00 price objective on the stock. Wall Street Zen downgraded shares of NovoCure from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NovoCure in a report on Thursday, August 27th. Finally, Zacks Research upgraded NovoCure from a “strong sell” rating to a “hold” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, NovoCure has a consensus rating of “Hold” and an average target price of $20.80.
NovoCure Stock Down 1.7%
Shares of NVCR traded down $0.22 on Friday, hitting $12.89. 631,485 shares of the stock traded hands, compared to its average volume of 1,678,152. The company has a market capitalization of $1.50 billion, a PE ratio of -9.93 and a beta of 0.99. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89. The business has a 50 day simple moving average of $15.88 and a 200 day simple moving average of $14.79. NovoCure has a one year low of $9.82 and a one year high of $21.45.
NovoCure (NASDAQ:NVCR – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.14. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The firm had revenue of $193.40 million during the quarter, compared to analyst estimates of $182.28 million. During the same period in the previous year, the business posted ($0.33) earnings per share. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. As a group, equities analysts forecast that NovoCure will post -1.21 earnings per share for the current fiscal year.
Institutional Investors Weigh In On NovoCure
Several institutional investors have recently made changes to their positions in NVCR. Quantinno Capital Management LP raised its holdings in shares of NovoCure by 23.7% in the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock worth $27,112,000 after buying an additional 477,128 shares during the period. Renaissance Technologies LLC increased its stake in NovoCure by 11.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,551,554 shares of the medical equipment provider’s stock worth $16,912,000 after buying an additional 163,800 shares during the period. Dimensional Fund Advisors LP increased its stake in NovoCure by 27.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 960,056 shares of the medical equipment provider’s stock worth $10,462,000 after buying an additional 207,913 shares during the period. Allianz Asset Management GmbH bought a new stake in NovoCure during the 2nd quarter valued at about $2,248,000. Finally, California State Teachers Retirement System boosted its position in NovoCure by 43.6% in the 1st quarter. California State Teachers Retirement System now owns 142,561 shares of the medical equipment provider’s stock valued at $1,554,000 after buying an additional 43,257 shares during the period. Institutional investors own 84.61% of the company’s stock.
NovoCure News Summary
Here are the key news stories impacting NovoCure this week:
- Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. The company’s adjusted loss of $0.09 per share also beat expectations, while the loss narrowed from $0.33 per share a year earlier. NovoCure Q3 earnings report
- Positive Sentiment: The company raised its 2026 financial guidance, signaling confidence in ongoing revenue growth and execution. The improved outlook was a favorable element of the earnings release, although investors appear focused on the pace of commercial adoption. NovoCure raises 2026 guidance
- Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 in pancreatic cancer. The partnership could expand the company’s clinical pipeline and provide another potential application for its technology, though it remains an early-stage opportunity. NovoCure and Verastem collaboration
- Negative Sentiment: Management said adoption of Optune Pax has been slower because of Revolution Medicines’ daraxonrasib, raising concerns that competing pancreatic-cancer treatment options could delay or limit uptake. Wedbush characterized the treatment as a potential market disruption rather than direct competition, but the issue appears to have overshadowed the earnings beat. Optune Pax adoption and daraxonrasib
NovoCure Company Profile
NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.
The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.
See Also
- Five stocks we like better than NovoCure
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
